Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase NA 2Phase 2 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 1Thrombosis 1Pulmonary Embolism 1Neoplasms 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × apixaban × Clear all
NCT02366871 2020-03-31

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

University of Colorado, Denver

Phase 2 Completed
400 enrolled 16 charts
Classical hematology

Venous Thromboembolism

NCT00320255 2016-08-16

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

Bristol-Myers Squibb

Phase 2 Completed
130 enrolled 22 charts

Neoplasms, Pulmonary Embolism, Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡